title: [ESWL in hemophilia B].
abstract: One of the most dramatic dangers in treating nephrolithiasis by ESWL is the development of intra- and perirenal bleeding, which requires therapeutic intervention. Even in patients whose blood parameters suggest they are healthy, hematomas are found in up to 80%. Therefore, ESWL must be regarded as contraindicated in patients with blood disorders. A case of a patient suffering from hemophilia B and from a large renal pelvic stone is reported, whom we treated by ESWL twice after sufficient substitution. X-ray revealed that the patient was stone-free on the 25th day after the first ESWL session. ESWL. A review of the literature is presented.
authors.affiliation: Klinik für Urologie, Medizinische Hochschule Hannover.
authors.forename: R
authors.initials: R
authors.lastname: Schlick
authors.forename: M
authors.initials: M
authors.lastname: Djamilian
authors.forename: W
authors.initials: W
authors.lastname: de Riese
authors.forename: M
authors.initials: M
authors.lastname: Truss
authors.forename: E P
authors.initials: EP
authors.lastname: Allhoff
authors.forename: U
authors.initials: U
authors.lastname: Jonas
mesh_terms: D000328:Adult; D000075202:Contraindications; D005164:Factor IX / Q000627:therapeutic use; D002836:Hemophilia B / Q000097:blood / Q000150:complications*; D006801:Humans; D007669:Kidney Calculi / Q000097:blood / Q000150:complications* / Q000628:therapy; D008096:Lithotripsy; D008297:Male; D010314:Partial Thromboplastin Time; D011292:Premedication; D012307:Risk Factors
chemical_list: D005164:Factor IX
vernacular_title: ESWL bei Hämophilie B.